CL2023001562A1 - Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico - Google Patents
Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémicoInfo
- Publication number
- CL2023001562A1 CL2023001562A1 CL2023001562A CL2023001562A CL2023001562A1 CL 2023001562 A1 CL2023001562 A1 CL 2023001562A1 CL 2023001562 A CL2023001562 A CL 2023001562A CL 2023001562 A CL2023001562 A CL 2023001562A CL 2023001562 A1 CL2023001562 A1 CL 2023001562A1
- Authority
- CL
- Chile
- Prior art keywords
- lupus erythematosus
- treatment methods
- cutaneous
- systemic lupus
- systemic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121194P | 2020-12-03 | 2020-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001562A1 true CL2023001562A1 (es) | 2023-12-15 |
Family
ID=79024222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001562A CL2023001562A1 (es) | 2020-12-03 | 2023-05-31 | Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240018246A1 (https=) |
| EP (1) | EP4255392A1 (https=) |
| JP (1) | JP2024501430A (https=) |
| KR (1) | KR20230119664A (https=) |
| CN (1) | CN116963716A (https=) |
| AR (1) | AR124247A1 (https=) |
| AU (1) | AU2021391803A1 (https=) |
| CA (1) | CA3203971A1 (https=) |
| CL (1) | CL2023001562A1 (https=) |
| CO (1) | CO2023008272A2 (https=) |
| IL (1) | IL303279A (https=) |
| MX (1) | MX2023006474A (https=) |
| PE (1) | PE20231678A1 (https=) |
| TW (1) | TW202222829A (https=) |
| WO (1) | WO2022120144A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118638234B (zh) * | 2024-07-04 | 2025-10-14 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1454215B (zh) * | 1999-11-15 | 2013-01-02 | 米勒腾尼生物技术有限公司 | 树突状细胞特异的抗原结合片段、组合物及其使用方法、被其识别的抗原及由其获得的细胞 |
| AU2013359419B2 (en) * | 2012-12-10 | 2018-03-15 | Biogen Ma Inc. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
| CN109535254B (zh) * | 2013-12-24 | 2022-06-24 | 安斯泰来制药株式会社 | 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物 |
| CN109475623B (zh) | 2016-04-28 | 2023-05-26 | 比奥根Ma公司 | 用于临床使用抗血树突细胞抗原2抗体的药物组合物和给药方案 |
-
2021
- 2021-12-03 AU AU2021391803A patent/AU2021391803A1/en active Pending
- 2021-12-03 IL IL303279A patent/IL303279A/en unknown
- 2021-12-03 EP EP21827347.2A patent/EP4255392A1/en active Pending
- 2021-12-03 TW TW110145254A patent/TW202222829A/zh unknown
- 2021-12-03 MX MX2023006474A patent/MX2023006474A/es unknown
- 2021-12-03 KR KR1020237022397A patent/KR20230119664A/ko active Pending
- 2021-12-03 JP JP2023533928A patent/JP2024501430A/ja active Pending
- 2021-12-03 CA CA3203971A patent/CA3203971A1/en active Pending
- 2021-12-03 US US18/038,911 patent/US20240018246A1/en active Pending
- 2021-12-03 WO PCT/US2021/061764 patent/WO2022120144A1/en not_active Ceased
- 2021-12-03 CN CN202180091232.0A patent/CN116963716A/zh active Pending
- 2021-12-03 AR ARP210103370A patent/AR124247A1/es unknown
- 2021-12-03 PE PE2023001760A patent/PE20231678A1/es unknown
-
2023
- 2023-05-31 CL CL2023001562A patent/CL2023001562A1/es unknown
- 2023-06-23 CO CONC2023/0008272A patent/CO2023008272A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023006474A (es) | 2023-08-16 |
| KR20230119664A (ko) | 2023-08-16 |
| AU2021391803A1 (en) | 2023-07-06 |
| CA3203971A1 (en) | 2022-06-09 |
| CO2023008272A2 (es) | 2023-09-29 |
| AR124247A1 (es) | 2023-03-01 |
| EP4255392A1 (en) | 2023-10-11 |
| AU2021391803A9 (en) | 2024-09-26 |
| WO2022120144A1 (en) | 2022-06-09 |
| US20240018246A1 (en) | 2024-01-18 |
| CN116963716A (zh) | 2023-10-27 |
| JP2024501430A (ja) | 2024-01-12 |
| TW202222829A (zh) | 2022-06-16 |
| IL303279A (en) | 2023-07-01 |
| PE20231678A1 (es) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018012506A2 (es) | Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre | |
| EA202091333A1 (ru) | Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний | |
| MX2022012991A (es) | Anticuerpos anti-vista humanos y uso de estos. | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| CL2018002763A1 (es) | Moléculas de unión a bcma y métodos de uso de las mismas. | |
| CL2019001874A1 (es) | Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos. | |
| UY38889A (es) | Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15r¿ y su uso | |
| AR110645A1 (es) | Anticuerpos anti-hla-g y uso de los mismos | |
| CL2018001334A1 (es) | Anticuerpos y conjugados anticuerpo-fármaco anti-5t4. | |
| MX2021006238A (es) | Metodos para tratamiento que usan terapia celular adoptiva. | |
| CO2020006865A2 (es) | Composiciones y métodos para el agotamiento de células cd5+ | |
| CL2021001201A1 (es) | Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn | |
| MX421741B (es) | Inmunoterapia con receptores de antígeno quimérico y uso de la misma | |
| MX2021006393A (es) | Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas. | |
| MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
| CR20210373A (es) | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp | |
| CO2021007060A2 (es) | Péptidos inmunogénicos con motivos de oxidorreductasa mejorados | |
| CO2023008272A2 (es) | Métodos de tratamiento del lupus eritematoso cutáneo y lupus eritematoso sistémico | |
| MX2024004652A (es) | Pautas posologicas para la movilizacion de celulas madre y progenitoras hematopoyeticas. | |
| MX2020009532A (es) | Oligonucleotidos modificados para uso en el tratamiento de tauopatias. | |
| AR084263A1 (es) | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) | |
| MX2022009628A (es) | Métodos para el tratamiento de la esclerodermia y padecimientos relacionados. | |
| BR112022018478A2 (pt) | Dispositivo de câmara celular implantável e usos do mesmo | |
| MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. |